Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brentuximab vedotin · 2 trials · 2 indications
As assessed by the Lugano criteria for PTCL(16) and the global response score for CTCL(17)
| Arm | Type | Description |
|---|---|---|
| Part A: Pembrolizumab and Brentuximab +AD | EXPERIMENTAL | - |
| Part B: De-Escalation | EXPERIMENTAL | - |
| Part C: Standard Risk Arm | EXPERIMENTAL | - |
| Brentuximab vedotin (brentuximab) and pembrolizumab | EXPERIMENTAL | All subjects are scheduled to receive up to 16 cycles of combinatorial treatment with brentuximab + pembrolizumab, followed by up to 19 additional cycles of pembrolizumab monotherapy. After receiving 35 total doses of pembrolizumab (i.e. scheduled for 16 doses in the combinatorial setting and 8 doses as monotherapy), a subject's pembrolizumab treatment will be complete. |
| Name | Type | Description |
|---|---|---|
| Brentuximab vedotin | DRUG | Given by IV (vein) |
| Doxorubicin Hydrochloride | DRUG | Given by IV (vein) |
| Pembrolizumab | DRUG | Given by IV (vein) |
| Dacarbazine | DRUG | Given by IV (vein) |
Inclusion Criteria: 1. Treatment-naïve, HL subjects with Ann Arbor stage III, IV, or stage II with bulky disease (\>10 cm). 2. Histologically confirmed cHL according to the current World Health Organization Classification (nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted, ...
Brentuximab vedotin is an investigational antibody-drug conjugate being studied for the treatment of T-Cell Lymphoma and Hodgkin Lymphoma. It is currently in Phase 2 clinical development for these oncology indications. The drug is being evaluated in combination with other agents, including pembrolizumab, in clinical trials.
Brentuximab vedotin is a monoclonal antibody, classified as an antibody-drug conjugate. It is designed to target CD30, a protein expressed on the surface of certain lymphoma cells. By binding to CD30, the drug delivers a cytotoxic agent directly to the cancer cells.
Brentuximab vedotin is being developed by Merck & Company, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with T-Cell Lymphoma and Hodgkin Lymphoma.
Brentuximab vedotin is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in active clinical trials for the treatment of T-Cell Lymphoma and Hodgkin Lymphoma.
Brentuximab vedotin is being evaluated in two Phase 2 clinical trials. NCT05313243 is studying the drug in combination with pembrolizumab in patients with relapsed or refractory T-cell lymphoma. NCT05922904 is evaluating PET-adapted brentuximab vedotin and pembrolizumab with doxorubicin and dacarbazine in classic Hodgkin lymphoma.
Brentuximab vedotin is the generic name for the drug also known as Adcetris. The drug is being studied under the name brentuximab vedotin in clinical trials for T-Cell Lymphoma and Hodgkin Lymphoma.